<DOC>
	<DOCNO>NCT02495896</DOCNO>
	<brief_summary>This pilot phase Ib trial study side effect best dose recombinant EphB4-HSA fusion protein give together standard chemotherapy regimen treat patient solid tumor spread place body usually cure controlled treatment ( advanced ) spread place body ( metastatic ) . Drugs use chemotherapy , recombinant EphB4-HSA fusion protein , paclitaxel albumin-stabilized nanoparticle formulation , gemcitabine hydrochloride , docetaxel , cisplatin , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . It yet know whether standard chemotherapy regimen effective recombinant ephB4-HSA fusion protein treat advanced metastatic solid tumor .</brief_summary>
	<brief_title>Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens Treating Patients With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To document safety tolerability sEphB4-HSA ( recombinant ephB4-HSA fusion protein ) intravenously ( IV ) weekly administer combination : arm A ) gemcitabine ( gemcitabine hydrochloride ) nab-paclitaxel ( paclitaxel albumin-stabilized nanoparticle formulation ) , arm B ) docetaxel , arm C ) gemcitabine cisplatin . SECONDARY OBJECTIVES : I . To describe adverse event profile sEphB4-HSA IV weekly administer combination : arm A ) gemcitabine nab-paclitaxel , arm B ) docetaxel , arm C ) gemcitabine cisplatin . II . To characterize pharmacokinetics sEphB4-HSA combine : arm A ) gemcitabine nab-paclitaxel , arm B ) docetaxel , arm C ) gemcitabine cisplatin . III . To assess , preliminary fashion , anti-tumor efficacy sEphB4-HSA combination various chemotherapy regimens 4 cohort separately : Arm A cohort 1-patients advance pancreatic cancer ; Arm B cohort 2-patients head neck cancer ; Arm B cohort 3-patients non-small cell lung cancer ; Arm C cohort 3 : patient cholangiocarcinoma . TERTIARY OBJECTIVES : I . To evaluate expression EPH receptor B4 ( EphB4 ) ephrinB2 archival tumor sample explore potential association outcome . II . To bank specimen future correlative biomarkers study base result ongoing biomarkers analyse phase I sEphB4-HSA single agent . OUTLINE : This dose de-escalation study recombinant EphB4-HSA fusion protein . Patients assign 1 3 treatment arm . ARM A : Patients receive recombinant EphB4-HSA fusion protein IV 1 hour day 1 , 8 , 15 , 22 ( begin course 2 ) , paclitaxel albumin-stabilized nanoparticle formulation IV 30 minute gemcitabine hydrochloride IV 30 minute day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . ARM B : Patients receive recombinant EphB4-HSA fusion protein IV 1 hour day 1 , 8 , 15 ( begin course 2 ) docetaxel IV 1 hour day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . ARM C : Patients receive recombinant EphB4-HSA fusion protein IV 1 hour day 1 , 8 , 15 ( begin course 2 ) , cisplatin IV 120 minute gemcitabine hydrochloride IV 30 minute day 1 8 . Courses repeat every 21 day absence disease progression unacceptable toxicity . In arm , patient chemotherapy relate toxicity may continue treatment recombinant EphB4-HSA fusion protein alone . Patients toxicity relate recombinant EphB4-HSA fusion protein may continue treatment chemotherapy discretion investigator . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<criteria>Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patients must measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) version ( v ) 1.1 Patients must life expectancy least 12 week Patients must able comprehend provide write informed consent Women childbearing potential ( WOCBP ) male patient WOCBP partner must use adequate method contraception avoid pregnancy throughout study 12 week last dose investigational product manner risk pregnancy minimize ; WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal ; post menopause define : Amenorrhea &gt; = 12 consecutive month without another cause For woman irregular menstrual period hormone replacement therapy ( HRT ) , document serum follicle stimulate hormone ( FSH ) level &gt; 35 mIU/mL Women use oral contraceptive , hormonal contraceptive ( vagina product , skin patch , implant injectable product ) , mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) prevent pregnancy , practice abstinence partner sterile ( e.g. , vasectomy ) consider childbearing potential WOCBP must negative serum test ( minimum sensitivity 25 IU/L equivalent unit human chorionic gonadotropin [ HCG ] ) within 72 hour prior start investigational product Patients hepatitis B infection must appropriate antiviral therapy ARM A COHORT 1 : Patients must advance pancreatic adenocarcinoma ( unresectable metastatic ) ARM A COHORT 1 : Patients must receive prior therapy metastatic advance disease ; adjuvant therapy gemcitabine base allow long adjuvant treatment complete &gt; = 6 month diagnosis recurrent disease ARM A COHORT 1 : Absolute neutrophil count &gt; = 1,500/ul ARM A COHORT 1 : Platelet count &gt; = 100,000/ul ARM A COHORT 1 : Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2 x upper limit normal ( ULN ) ; liver metastases present must &lt; 5 X ULN ARM A COHORT 1 : Total bilirubin = &lt; 1.5 x ULN ARM A COHORT 1 : Creatinine = &lt; 1.5 x institutional ULN , creatinine clearance &gt; = 50 mL/min ( calculate CockcroftGault formula ) ARM A COHORT 1 : Serum albumin &gt; = 2.5 g/dL ARM B COHORT 2 : Patients must histologically confirm diagnosis head neck ( squamous cell ) carcinoma ARM B COHORT 2 : Patients must fail treatment platinum base therapy without cetuximab ; previous therapy platinum concurrent radiation follow progression disease within 6 month count failure one prior line cisplatin base therapy ARM B COHORT 2 : Absolute neutrophil count &gt; = 1,500/ul ARM B COHORT 2 : Platelet count &gt; = 100,000/ul ARM B COHORT 2 : AST ALT = &lt; 2 X ULN ; liver metastases present must &lt; 5 X ULN ARM B COHORT 2 : Total bilirubin = &lt; 1.5 x institutional upper limit normal ( IULN ) ARM B COHORT 2 : Serum albumin &gt; = 2.5 g/dL ARM B COHORT 2 : Creatinine = &lt; 1.5 x institutional ULN , creatinine clearance &gt; = 50 mL/min ( calculate CockcroftGault formula ) ARM B COHORT 3 : Patients must histologically confirm diagnosis nonsmall cell lung cancer ARM B COHORT 3 : Patients must fail one prior line systemic therapy treatment advance nonsmall cell lung cancer ; prior adjuvant therapy subsequent recurrence within 6 month completion therapy count one prior line systemic therapy patient eligible ARM B COHORT 3 : Absolute neutrophil count &gt; = 1,500/ul ARM B COHORT 3 : Platelet count &gt; = 100,000/ul ARM B COHORT 3 : AST ALT = &lt; 2 X ULN ; liver metastases present must &lt; 5 X ULN ARM B COHORT 3 : Total bilirubin = &lt; 1.5 x IULN ARM B COHORT 3 : Serum albumin &gt; = 2.5 g/dL ARM B COHORT 3 : Creatinine = &lt; 1.5 x institutional ULN , creatinine clearance &gt; = 50 mL/min ( calculate CockcroftGault formula ) ARM C COHORT 4 : Patients must histologically cytologically proven diagnosis advance ( unresectable metastatic ) gallbladder cancer cholangiocarcinoma candidate first line therapy gemcitabine cisplatin ARM C COHORT 4 : Patients must receive prior systemic chemotherapy advance metastatic disease ; prior adjuvant chemotherapy concurrent chemotherapy radiation allow complete &gt; = 6 month prior diagnosis recurrent disease ARM C COHORT 4 : Absolute neutrophil count &gt; = 1,500/ul ARM C COHORT 4 : Platelet count &gt; = 100,000/ul ARM C COHORT 4 : AST ALT = &lt; 5 x ULN ARM C COHORT 4 : Total bilirubin = &lt; 2 X IULN ARM C COHORT 4 : Serum albumin &gt; = 2.5 g/dL ARM C COHORT 4 : Creatinine = &lt; 1.5 x institutional ULN , creatinine clearance &gt; = 50 mL/min ( calculate CockcroftGault formula ) ARM C COHORT 4 : Patients decompression biliary tree within last 14 day , must stable bilirubin level confirm two measurement within 5 7 day ; ( second measurement must obtain within 7 day prior registration ) ; first second measurement must = &lt; 2 X IULN ; stability define second measurement one point high first Patients must receive anticancer therapy ( cytotoxic chemotherapy , target therapy radiation ) within past 28 day prior initiation study therapy Patients must active major systemic infection require systemic antibiotic 72 hour less prior first dose study drug Patients must untreated central nervous system ( CNS ) metastases ; patient whose CNS metastases treat surgery radiotherapy , long corticosteroid , neurologically stable may enrol Patients must follow : New York Heart Association ( NYHA ) class 3 4 congestive heart failure ; myocardial infarction within past 12 month , acute coronary syndrome , diabetes mellitus ketoacidosis chronic obstructive pulmonary disease ( COPD ) require hospitalization precede 6 month ; intercurrent medical condition contraindicates treatment sEphB4HSA place patient undue risk treatment related complication Patients must condition , include mental illness substance abuse , deem Investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result Patients must pregnant lactate Patients must dose warfarin full dose anticoagulation agent , include low molecular weight heparin , antithrombin agent , antiplatelet agent full dose aspirin within 7 day prior first dose study drug ; patient prophylactic dos lowmolecular weight heparin allow Patients must active bleeding last = &lt; 4 week otherwise know bleed diathesis Patients must correct QT ( QTc ) F ( Fridericia Correction Formula ) &gt; 480 2 3 electrocardiogram ( EKG 's ) ( first EKG = &lt; 480 , need repeat , first EKG &gt; 480 repeat twice total 3 EKG 's ) Patients must uncontrolled hypertension define systolic blood pressure ( SBP ) &gt; = 160 mmHg diastolic blood pressure ( DBP ) &gt; = 90 mmHg ; patient whose blood pressure control medically allow rescreened blood pressure ( BP ) control Patients must &gt; grade sensory neuropathy Patients must know human immunodeficiency virus ( HIV ) infection ARM A COHORT 1 : Patients must prior nabpaclitaxel exposure ARM A COHORT 1 : Patients must history slowly progressive dyspnea unproductive cough , condition sarcoidosis , silicosis , idiopathic pulmonary fibrosis , pulmonary hypersensitivity pneumonitis , multiple allergy ARM B COHORT 2 : Patients must prior exposure docetaxel ARM B COHORT 2 : Patients head neck cancer must radiologic evidence major arterial involvement ARM B COHORT 3 : Patients must prior exposure docetaxel ARM B COHORT 3 : Patients must one prior line systemic therapy advance nonsmall cell lung cancer ( include treatment target agent ) ; prior adjuvant therapy complete 6 month prior disease recurrence count prior line systemic therapy advance disease ARM B COHORT 3 : Patients must active clinically significant hemoptysis ARM B COHORT 3 : Patients must central lesion radiologic evidence arterial involvement ARM C COHORT 4 : Patients must prior cisplatin exposure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>